Cargando…

Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq

Diabetes mellitus is a disease with a high burden and prevalence and serious complications. Glycemic control is vital in delaying or preventing complications. Although many people do not take optimal doses, metformin is a cornerstone in managing type 2 diabetes mellitus (T2DM) in all guidelines. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Waeli, Dheyaa, Mohammed, Adel, Tahir, Imad, Al-Saeedi, Ali, Razzaq, Khdair, Abodhurais, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126465/
https://www.ncbi.nlm.nih.gov/pubmed/35646179
http://dx.doi.org/10.25122/jml-2021-0259
_version_ 1784712136673460224
author Al-Waeli, Dheyaa
Mohammed, Adel
Tahir, Imad
Al-Saeedi, Ali
Razzaq, Khdair
Abodhurais, Ali
author_facet Al-Waeli, Dheyaa
Mohammed, Adel
Tahir, Imad
Al-Saeedi, Ali
Razzaq, Khdair
Abodhurais, Ali
author_sort Al-Waeli, Dheyaa
collection PubMed
description Diabetes mellitus is a disease with a high burden and prevalence and serious complications. Glycemic control is vital in delaying or preventing complications. Although many people do not take optimal doses, metformin is a cornerstone in managing type 2 diabetes mellitus (T2DM) in all guidelines. This study determined the barriers interfering with optimal metformin dosage. A cross-sectional study was conducted in Thi-Qar Specialized, Diabetes, Endocrine and Metabolism Center (TDEMC) at Thi-Qar, southern Iraq, from January 2019 to January 2020. 475 patients (274 females and 201 males) were included, and examination and lab investigations were performed. Only 22 (4.6%) patients took the optimal dose with no differences between gender. Of those who took metformin, 255 (74%) took it as a regular pill, 79 (23%) as a combined form with sulfonylureas (SUs), while only 10 (0.3%) took combined pills with Dipeptidyl Peptidase-4 inhibitors (DPP4i). 188 patients (65%) took metformin with meals, 84 (29%) before meals, and 19 (6%) after meals. Ignorance caused poor adherence to optimal dose in 165 patients (38.6%), neglect in 75 (17.6%), the cost in 5 (1.2%), 11 patients (2.6%) thought they did not need metformin, 37(8.7%) and 12 (2.8%) blame side effects and shortage of supply from public health care clinics (PHCC) as a cause, respectively. The rest of the patients had more than one cause. The most common side effects were abdominal pain and bloating, 5.9% and 3.8%, respectively. Other side effects were diarrhea in 0.2%, and 7.8% of patients developed more than one side effect. Ignorance and neglect were major obstacles, so educating doctors and patients and supplying the patient with optimal doses through PHCC may overcome the problem.
format Online
Article
Text
id pubmed-9126465
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-91264652022-06-01 Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq Al-Waeli, Dheyaa Mohammed, Adel Tahir, Imad Al-Saeedi, Ali Razzaq, Khdair Abodhurais, Ali J Med Life Original Article Diabetes mellitus is a disease with a high burden and prevalence and serious complications. Glycemic control is vital in delaying or preventing complications. Although many people do not take optimal doses, metformin is a cornerstone in managing type 2 diabetes mellitus (T2DM) in all guidelines. This study determined the barriers interfering with optimal metformin dosage. A cross-sectional study was conducted in Thi-Qar Specialized, Diabetes, Endocrine and Metabolism Center (TDEMC) at Thi-Qar, southern Iraq, from January 2019 to January 2020. 475 patients (274 females and 201 males) were included, and examination and lab investigations were performed. Only 22 (4.6%) patients took the optimal dose with no differences between gender. Of those who took metformin, 255 (74%) took it as a regular pill, 79 (23%) as a combined form with sulfonylureas (SUs), while only 10 (0.3%) took combined pills with Dipeptidyl Peptidase-4 inhibitors (DPP4i). 188 patients (65%) took metformin with meals, 84 (29%) before meals, and 19 (6%) after meals. Ignorance caused poor adherence to optimal dose in 165 patients (38.6%), neglect in 75 (17.6%), the cost in 5 (1.2%), 11 patients (2.6%) thought they did not need metformin, 37(8.7%) and 12 (2.8%) blame side effects and shortage of supply from public health care clinics (PHCC) as a cause, respectively. The rest of the patients had more than one cause. The most common side effects were abdominal pain and bloating, 5.9% and 3.8%, respectively. Other side effects were diarrhea in 0.2%, and 7.8% of patients developed more than one side effect. Ignorance and neglect were major obstacles, so educating doctors and patients and supplying the patient with optimal doses through PHCC may overcome the problem. Carol Davila University Press 2022-04 /pmc/articles/PMC9126465/ /pubmed/35646179 http://dx.doi.org/10.25122/jml-2021-0259 Text en ©2022 JOURNAL of MEDICINE and LIFE https://creativecommons.org/licenses/by/3.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Original Article
Al-Waeli, Dheyaa
Mohammed, Adel
Tahir, Imad
Al-Saeedi, Ali
Razzaq, Khdair
Abodhurais, Ali
Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq
title Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq
title_full Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq
title_fullStr Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq
title_full_unstemmed Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq
title_short Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq
title_sort barriers against the use of an optimal dose of metformin among patients with t2dm in thi-qar province, iraq
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126465/
https://www.ncbi.nlm.nih.gov/pubmed/35646179
http://dx.doi.org/10.25122/jml-2021-0259
work_keys_str_mv AT alwaelidheyaa barriersagainsttheuseofanoptimaldoseofmetforminamongpatientswitht2dminthiqarprovinceiraq
AT mohammedadel barriersagainsttheuseofanoptimaldoseofmetforminamongpatientswitht2dminthiqarprovinceiraq
AT tahirimad barriersagainsttheuseofanoptimaldoseofmetforminamongpatientswitht2dminthiqarprovinceiraq
AT alsaeediali barriersagainsttheuseofanoptimaldoseofmetforminamongpatientswitht2dminthiqarprovinceiraq
AT razzaqkhdair barriersagainsttheuseofanoptimaldoseofmetforminamongpatientswitht2dminthiqarprovinceiraq
AT abodhuraisali barriersagainsttheuseofanoptimaldoseofmetforminamongpatientswitht2dminthiqarprovinceiraq